Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis

[1]  P. Christadoss,et al.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. , 2002, The Journal of clinical investigation.

[2]  S. Fuchs,et al.  Blockade of CD40 Ligand Suppresses Chronic Experimental Myasthenia Gravis by Down-Regulation of Th1 Differentiation and Up-Regulation of CTLA-41 , 2001, The Journal of Immunology.

[3]  F. Shi,et al.  Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis1 , 2001, The Journal of Immunology.

[4]  S. Fuchs,et al.  Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1 , 2000, The Journal of Immunology.

[5]  L. Steinman.  Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. , 2000, Journal of autoimmunity.

[6]  E. Sercarz.  Driver clones and determinant spreading. , 2000, Journal of autoimmunity.

[7]  S. Fuchs,et al.  Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. , 1999, The Journal of clinical investigation.

[8]  V. Tuohy,et al.  Spontaneous Regression of Primary Autoreactivity during Chronic Progression of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis , 1999, The Journal of experimental medicine.

[9]  S. Tzartos,et al.  Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients , 1999, Clinical and experimental immunology.

[10]  Zeng-Yu Wang,et al.  T Cell Recognition of the Acetylcholine Receptor in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.

[11]  Willcox,et al.  Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies , 1998, Clinical and experimental immunology.

[12]  S. Fuchs,et al.  Modulation of the anti‐acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor , 1998, European journal of immunology.

[13]  S. Miller,et al.  Evolution of the T‐Cell Repertoire during the Course of Experimental Immune‐Mediated Demyelinating Diseases , 1995, Immunological reviews.

[14]  A. Vincent,et al.  Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. , 1994, Immunology letters.

[15]  S. Tzartos,et al.  Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor α subunit , 1992 .

[16]  E. Sercarz,et al.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen , 1992, Nature.

[17]  A. Vincent,et al.  The human muscle nicotinic acetylcholine receptor alpha‐subunit exist as two isoforms: a novel exon. , 1990, The EMBO journal.

[18]  Z. Vogel,et al.  Species specificity of anti-acetylcholine receptor antibodies elicited by synthetic peptides. , 1987, Biochemistry.

[19]  S. Pizzighella,et al.  Localization of a highly immunogenic region on the acetylcholine receptor α-subunit , 1986 .

[20]  I. Silman,et al.  Immunochemical studies on acetylcholine receptor from Torpedo californica. , 1977, Immunochemistry.

[21]  J. Palace,et al.  Immunogenicity of human recombinant acetylcholine receptor alpha subunit: cytoplasmic epitopes dominate the antibody response in four mouse strains. , 1994, Autoimmunity.

[22]  S. Tzartos,et al.  The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis. , 1991, Autoimmunity.